A Phase 3 interventional study of Faricimab PFS Configuration in Neovascular Age-related Macular Degeneration and Diabetic Macular Edema, sponsored by Hoffmann-La Roche. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-10.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing faricimab in Macular Edema — 1 open to participants now, 3 under way, none of them phase 3. faricimab · Macular Edema.
Among the 13 studies testing faricimab in Macular Edema, this one is the 11th largest by enrollment, is one of 3 that started in 2022, is one of 7 in phase 3, and was the 10th registered.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
Browse Macular Edema studies →1 of the 13 studies testing faricimab in Macular Edema is open now. Recruiting first, the newest first:
Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust
Ages 18+
faricimab: first FDA approval 2022 (VABYSMO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2022.
This study's enrollment of 35 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Median enrollment 229 across the 13 interventional studies. Of the 8 that completed or were terminated, 8 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 13 have an industry lead sponsor. The 6 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
28 studies in Macular Edema by Hoffmann-La Roche: 1 open now, 5 under way, 1 of them phase 3. Of 23 finished, 17 (74%) have results posted.
Among the 28 studies in Macular Edema by Hoffmann-La Roche, this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2022, is one of 14 in phase 3, and was the 20th registered.
Hoffmann-La Roche’s Macular Edema studies by the year they started, since 2007.
2 of the studies testing faricimab in Macular Edema that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05610319McMaster UniversityTreat & Extend Versus Fixed Dosing With Faricimab for Management of Diabetic Macular Edema: A Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial | 2026-12 |
| NCT05224102Genentech, Inc.A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema | 2027-01-26 |
Add all 2 to your calendar (.ics) → With an account.
Among the 13 studies testing faricimab in Macular Edema, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 28 in Macular Edema:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This Phase IIIb, single-arm, open-label multicenter clinical in-use study in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) is designed to assess the ability of the intended users, healthcare providers (HCPs), to follow the Instructions for Use to perform an intravitreal (IVT) injection using the 6-milligram (mg) faricimab prefilled syringe (PFS) configuration per the intended use. Any adverse events occurring during the 7-day study reporting period will be summarized.
758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.
This study's enrollment of 35 is below the median of 56 across 586 interventional studies indexed under Macular Edema.
Browse Macular Edema studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination Product: Faricimab PFS Configuration
Participants will receive a single intravitreal (IVT) injection of the 6-milligram (mg) faricimab dose formulation delivered via prefilled syringe (PFS) with a co-packaged injection filter needle.
Also known as: VABYSMO™, RO6867461, RG7716
Percentage of Injection Procedures With Successful Completions on Critical Tasks Performed by Healthcare Providers in the Use of the Faricimab Prefilled Syringe Configuration
Thirteen healthcare providers (HCP; seven retina specialists and six assistants) across three sites participated in the study, and they worked mostly in pairs to administer a single intravitreal (IVT) injection of 6-mg faricimab to each of the 35 patients using the prefilled syringe (PFS). For each IVT injection, two Human Factors (HF) observers were positioned such that they could clearly observe the entire preparation and administration process. Each HCP team (i.e., retina specialist alone or retina specialist with assistant, as per local procedure) were asked to perform all preparation and administration steps in view of the HF observers. Critical tasks were observed by the HF observers who documented HCP performance using an assessment checklist. A successful task completion for each critical task was defined as normal use without use error, and the percentages of successful completions are calculated out of the total 35 PFS IVT injections administered.
Time frame: Day 1
Percentage of Injection Procedures With Use Errors on Critical Tasks Performed by Healthcare Providers in the Use of the Faricimab Prefilled Syringe Configuration
Thirteen healthcare providers (HCP) across 3 sites participated in the study, and they worked mostly in pairs to administer a single intravitreal (IVT) injection of 6-mg faricimab to each of the 35 patients using the prefilled syringe (PFS). For each IVT injection, two Human Factors (HF) observers were positioned such that they could clearly observe the entire preparation and administration process. Each HCP team (i.e., retina specialist alone or retina specialist with assistant, as per local procedure) were asked to perform all preparation and administration steps in view of the HF observers. Critical tasks were observed by the HF observers who documented HCP performance using an assessment checklist. A use error was defined as user action or lack of user action while using the medical device that leads to a different result than that intended by the manufacturer or expected by the user. The percentages of use errors are calculated out of the total 35 PFS IVT injections administered.
Time frame: Day 1
| Milestone | Faricimab PFS Configuration |
|---|---|
| Started | 35 |
| Completed | 35 |
| Not completed | 0 |
Thirteen healthcare providers (HCP; seven retina specialists and six assistants) across three sites participated in the study, and they worked mostly in pairs to administer a single intravitreal (IVT) injection of 6-mg faricimab to each of the 35 patients using the prefilled syringe (PFS). For each IVT injection, two Human Factors (HF) observers were positioned such that they could clearly observe the entire preparation and administration process. Each HCP team (i.e., retina specialist alone or retina specialist with assistant, as per local procedure) were asked to perform all preparation and administration steps in view of the HF observers. Critical tasks were observed by the HF observers who documented HCP performance using an assessment checklist. A successful task completion for each critical task was defined as normal use without use error, and the percentages of successful completions are calculated out of the total 35 PFS IVT injections administered.
| Percentage of injection procedures | Faricimab PFS Configuration |
|---|---|
| Open Folding Box | 100 |
| Remove Leaflet and Tray with Syringe from Folding Box | 100 |
| Remove Supplied Injection Filter Needle from Folding Box | 100 |
| Peel Lid off the Tray | 100 |
| Aseptically Remove Syringe from Tray | 100 |
| Split Open Pouch | 100 |
| Aseptically Remove Injection Filter Needle | 100 |
| Remove Syringe Tip Cap | 100 |
| Aseptically Attach Supplied Injection Filter Needle Onto Syringe Luer Connector | 100 |
| Remove Injection Filter Needle Cap | 100 |
| Hold Syringe Upright | 100 |
| If Air Bubbles are Present, Tap to Force Air Bubbles to the Top of the Syringe | 100 |
| Slowly Push the Plunger to Align the Stopper to the Syringe 0.05 mL Dose Mark | 100 |
| Insert Injection Filter Needle at the Injection Site | 100 |
| Inject Slowly Until Stopper Reaches the End of the Syringe Barrel to Deliver the Volume of 0.05 mL | 100 |
| Remove Injection Filter Needle from the Injection Site | 100 |
| Dispose of Used Syringe with Uncapped Needle in a Sharps Disposal Container | 100 |
Thirteen healthcare providers (HCP) across 3 sites participated in the study, and they worked mostly in pairs to administer a single intravitreal (IVT) injection of 6-mg faricimab to each of the 35 patients using the prefilled syringe (PFS). For each IVT injection, two Human Factors (HF) observers were positioned such that they could clearly observe the entire preparation and administration process. Each HCP team (i.e., retina specialist alone or retina specialist with assistant, as per local procedure) were asked to perform all preparation and administration steps in view of the HF observers. Critical tasks were observed by the HF observers who documented HCP performance using an assessment checklist. A use error was defined as user action or lack of user action while using the medical device that leads to a different result than that intended by the manufacturer or expected by the user. The percentages of use errors are calculated out of the total 35 PFS IVT injections administered.
| Percentage of injection procedures | Faricimab PFS Configuration |
|---|---|
| Percentage of Injection Procedures With Use Errors on Critical Tasks Performed by Healthcare Providers in the Use of the Faricimab Prefilled Syringe Configuration | 0 |
Collected over From Day 1 to Day 7. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Faricimab PFS Configuration | 0/35 (0%) | 0/35 (0%) | 1/35 (2.9%) |
| Event | Faricimab PFS Configuration |
|---|---|
| Eye irritationEye disorders | 1/35 |
All enrolled patients
| Age, Continuous(Years) | Faricimab PFS Configuration |
|---|---|
| Mean | 74.7 ± 10.7 |
| Sex: Female, Male(Participants) | Faricimab PFS Configuration |
|---|---|
| Female | 16 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | Faricimab PFS Configuration |
|---|---|
| Hispanic or Latino | 1 |
| Not Hispanic or Latino | 32 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Faricimab PFS Configuration |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 33 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Underlying Condition in Study Eye(Participants) | Faricimab PFS Configuration |
|---|---|
| DME Only | 12 |
| nAMD Only | 22 |
| Both DME and nAMD | 1 |
Plan to share: No — Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Oct 2022 to primary completion in Nov 2022, 0 months.
Results were first posted in Oct 2023, 11 months after primary completion.
Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 0 months is below that.
Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Faricimab